<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 377 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page376.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=377">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 377 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 377</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=377"><img src="../thumb/377.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>340 / 2020-04                                                                 Biologicals - 26
   SYNAGIS, Abbvie [P/S] &      Side effects: Loc./ anaphylact.reacts., naus., headache, fev., chills,   Side effects: Cytomegalovir.infect., sepsis, UTI, H.simplex, oral
   Palivizumab                  flush, lightheadedn., backache, IgA sensitisat., imp.effic.of live at-  monilias., neoplast.malign., lymphopen., leucopen., thrombocytopen.,
   Indications: Respirat.syncytial virus (RSV) prophylax. in high risk   tenuat. vir.vacc.  neutropen., antibod.induc.cross reacts., allerg. reacts., anaphylact.
   paed.pts. Safety & effic.est.in infts.with bronchopulm.dysplas./  Special precautions: Concom.passive-act. immunisat. with tetanus   shock, cytokin.rel.syndr., ser. sickn., tachycard., hypotens., periph.
   prem. infts.of &lt;35 wks.& childr.with haemodynamic. signif. con-  toxoid by IMI at diff.site poss., delay other vaccinat.ie.live virus for 3   thrombophlebit., dyspn., GI disturbs., prurit., rash, arthralg., myalg.,
   genit.heart dis.             mnths., IM inj.not advoc.in bleed disords., admin. in.div.dos.at diff.  chills, fev., infus.site pain.
   (S4) SOL.FOR INJ, 50/30.1/0148 100 mg/ml  sites if large vol. (&gt;2 ml for childr./ &gt;5 ml for adults) reqd., do not mix   Special precautions: Any anaphylact.react. dur. admin.C/I’s furth.
   3000492-001: 1x0,5 ml, R6 736,40  with other prods., if simultan.vaccinat.necess. immunoglobul. & vacc.   treatm., strict med.surveill.in hosp., adhere strict.to infus.rate as
   3000493-001: 1x1 ml, R13 472,80  should be admin.at diff.sites to avoid interf. with act.antib.resp., as in-  ser.S/E poss relat. to infus.rate, pts.who have already recd. rabbit im-
          st
   Dosage: Admin.1  dos.prior to RSV season with subseq.dos.mnthly   fect.dis.transmiss. cannot be tot.excl.consid.vaccinat.where appropr.  munoglobul., monit.bld.counts x2 wks. follow. end of treatm., consid.
   throughout season. To avoid reinfect.childr.receiv.Synagis who be-  reduc.dos.in organ transplant. if platel.count is &lt; 80 x 10 9  platelets/L,
   came infect.should contin.with mnthly.dos.for durat.of RSV season.  TETAVAX, Sanofi Aventis [P/S]  consid. discont.in organ transplant.if persist.& sev. thrombocytopen.
                                                                               9
                                                                  9
   Recomm.dos: 15 mg/kg bm.IM once mnthly dur.anticipat. com-  Tetanus toxoid(purified) 40 IU/0,5 ml.  ( &lt; 50 x 10  cells/L) or leucopen. (&lt;1,5 x 10  cells/L) develops, infect.
   mun.RSV risk periods.        Indications: Booster act.tetanus immunisat.for long term prophylax.  risk mark.incr.in condit. protocols, risk of recurr.of init.malig.dis.
   Contraindications: Hist.of react.to other human. monoclonal   in adults, tetanus post-expos prophylax.with no prior vaccinat./vac-  incr., concom.bld./bld.derivat./other infus.esp. lipids not advis., lym-
   antibod.                     cinat.incompl. or unknown, neonat.tetanus prophylax.for women of   phoproliferat.disords.incr.by other concom.immunosuppress.agents.
   Side effects: Very common: Rash, pyrex. Common: Apnoea, inj.  reproduct.age and pregn.women not yet imunis.  Drug interactions: Excess.immunosuppress.risk & subseq. lym-
   site reacts. Uncommon: Thrombocytopen., convuls., urticar. Not   (S2) INJ. 29/30.1/0637.  phoproliferat.with cyclospor./ tacrolimus & mycophenolate mofetil,
   known: Anaphylax., anaphylact.shock incl.fatalit. Post market:   832693-006: 1x sngl.dos.prefilled syringe, R87,39  risk of system. infect.with live atten.vacc., antibody format. which
   Antibody respons.with appear.of no clinic.relevance.  Dosage: Admin by deep SC/IMI.  pos.reacts.with other rabbit immunoglobul.
   Warnings and special precautions: Allerg. react.risk.discont.if   Adults:
                                                          rd
   sev.react.occurs & re-admin. with caut.in case of mild.hypersens.re-  Prim.vaccinat.sched: 2 success.dos.at interv.of 1-2 mnths.  3  dos.  TRIMOVAX, Sanofi Aventis [P/S]
                                                              Live atten.Measles virus (Schwarz strain) 1 000 TCID 50, mumps
                                 st
                                               nd
   act., thrombocytopen., coagulat.disords., consid.delay. ther. in cases   (1  booster) admin.6-12 mnths aft.2  inj.
   of mod.to sev.ac.infect./febrile illn., not indic.for adult usage & anim.  Booster immunisat.for long-term prophylax: Sngl.dos of 0,5 ml   virus (Urabe strain) 5 000 TCID 50, rubella virus (Wistar strain)1000
                                                              TCID 50/0,5 ml.
   reproduct.studies not conduct., unknown if can cause foet.harm./ af-  10 yrs.aft.prim.dos.& every 10 yrs. throughout adult life.
   fect reproduct.capacity.     Post-expos.prophylax: Physic.to cleanse, debride wound & de-  Indications: Act.immunisat.for measles, mumps & rubella.
                                                              (S2) INJ. T/30.1/187. 0,5 ml.
                                termine likelihood of clostridium tenani presence for min.wound.
   SYNFLORIX, GSK [P/S]         0,5 ml tetanus toxoid IMI and complete immunisat. schedule where   792004-019: Sngl.dose syrng, R191,69
   Adsorb.pneumococcal.polysacchar. & non-typeable H influenzae   requir. See lit.for recommendat./ addit.human tetanus immuno-  Dosage: Sngl.0,5 ml SC/IM inj.
   (NTHi) prot.D conjug.vacc.in 0,5 ml dos.  globul.& antibiotic ther.  Contra-indications: Act./develop.ac.resp.infect. incl.act.untreat.
   Indications: Act.immunis.of infts.& childr.from 6 wks.-5 yrs against   Neonat.tetanus prophylax: Women of reproduct. age & pregn.  TB, immunocomprom.pts., prim. /second. immunodefic., pregn., egg
   dis.caus.by Streptococcus pneumon. serotypes [1,4,5,6B,7F, 9V, 14,   women not prev. immun: 2 dos.with a minimal interv.of 4 wks., the   prot./neomyc. allergy.
   18C, 19F & 23F] and ac.otit.med.caus.by non-typeable H influenzae   1st inj being pref. 90 days or more bef.deliv.  Side-effects: Hypertherm., lymphadenopathy, rash, malaise, rhi-
   (S2) SUSP FOR INJ. 43/30.2/0401  Contraindications: Hypersens.react./neurologic. disord.aft.prev.  nopharyngeal/ocul.catarrh., headache, arthralg., parotidit., con-
   714999-001: 1x pre-fill.sngl.dos.syr., R856,65  inj.of vacc., intravasc.route  vuls., encephalit.
   Dosage: Subj.receiv.1  dos.should complete course. IMI admin. Pre-  Side effects: Loc.reacts., trans.hypertherm., allerg. cutan.reacts.,   Special precautions: Allerg.condits., childr.with convuls.hist.to be
            st
   fer.sites are anterolat.. thigh in infts./deltoid musc.of upp.arm in childr.   dizzin., low BP, arthralgia, myalgia, headaches, neurologic.disords.  vaccinat.once 24 mnths.of age, allow swab.area to dry bef.admin., delay
   May be admin.concurr.with recomm.childhood vacc  Special precautions: Postpone vaccinat.in fev./ ac. dis & evolu-  vacc.for 3 mnths.follow.human immune globul.admin./ bld. transfus.
   Infts.6 wks-6 mnths: 3-dos.prim.series: Recomm. immunisat.  tiv.chron.dis., do not give booster dos. at interv.of less than 10 yrs.  TUBERCULIN PPD RT/23 2TU, Kahma Biotech [P/S]
   series to ensure optim. protect. consists of 4 dos.of 0,5 ml. Prim.  due to incr.risk of sev. loc.reacts., keep adrenaline avail.in case of   Tuberculin, purified protein derivative.
   inft. series: 3 dos.with 1  dos. giv.at 2 mnths.of age & with interv.  anaphylact.reacts.  Indications: Intraderm.skin test aid.for TB diagnos.
             st
   of at least 1 mnth.betw.dos. Boost. dos. recomm.at least 6 mnths   Warning: Inj.only healthy indiv., intraderm.route of admin.cannot be   (S2) INJ, 28/30.3/0356. 2TU/0,1 ml,
   aft.last prim. dos.          used, to prevent Arthus-type hypersens.reacts.boosters should not be   872938-027: 10x1,5 ml, R1 536,57
   2-dose prim.series: Alternativ.,a series consist.of 3 dos. of 0,5   giv.to adults who have either complet.a prim.series or receiv.booster   Dosage: For suspect. clinic.TB/test for immune respon. follow. vac-
   ml may be giv. The 1  dos.may be admin. from age of 2 mnths.,   dose within the prev.5 yrs., immunosuppress. treatm./immunodefic.  cinat: use 2TU. By intraderm. inj. admin. 0,1 ml in one superfic.layer
            st
   with a 2nd dose 2 mnths. later. A boost.dos.is recomm.at least 6   condit. decr. immune response theref.postpone vaccinat. to end of   of dermis in middle part of forearm. Interpret.test 48-72 hrs. aft.
   mnths. aft.the last.         treatm., vaccinat.pts.with chron. immunodepress. if subjacent dis.  inj.by measur.transvers.diam.of indurat.in mm. Excl. any surround.
   Preterm infts. born aft.at least 27 wks. of gestation.age:   allows even limit. antibody response.  erythematous zone.
   Recomm.immunisat.series consists of 4 dos.of 0,5 ml. Prim.inft.  Contraindications: Prev.sev.loc.react., prev.TB/ mycobact. dis.diagn.
   series: 3 dos. with 1st dos. giv.at 2 mnths.of age & with interv.  THYMOGLOBULINE, (Sanofi) Genzyme [P/S]  Side effects: Pain, itch./irrit.at inj.site, anaphylax., headache, fev.,
   of at least 1 mnth.betw.dos. Boost. dos. recomm.at least 6 mnths   Rabbit anti-human thymocyte immunoglobul. 25 mg, glycine 50 mg,   lymph node enlargem., urticar., vesiculat., skin necros.
   aft.last prim.dos.           NaCl 10 mg, mannitol 50 mg    Interactions Age/nutrit./immunosuppress. & vir. infects.can low.
   Prev.unvaccin.old.infts.& childr: Infts.7-11 mnths: 2 dos.of 0,5   Indications: Immunosuppress.in transplantat.: prophylax.& treatm.  tubercul.reactiv., prev.BCG vaccinat. & rec.non-tubercul. mycobact.
                            nd
                     rd
   ml with interv.of at least 1 mnth. betw.dos. 3  dos.recomm.in 2  yr.of   of solid organ graft reject.& ac.& chron.graft.vs.host dis.(GvHD)   infect.may give false posit.reacts., reduc.reactiv.aft.live vir. vaccinat.,
   life with interv.of at least 2 mnths. Childr.12 mnths. – 5 yrs: 2 dos.  prophylax.in haematopoiet.stem cell transplantat.(HSCT), sev.   HIV & M.tuberculos pts.have anergy for tuberculin, sev.TB tuberculin
   of 0,5 ml with interv.of at least 2 mnths. betw.dos.  aplast.anaem.when immune mechanism suspect./ when HLA iden-  reactiv.poss.suppress.
   Contra-indications: Intravasc.or intraderm. admin., not intend.for   tic.sibl.not avail./pt.old.than 45 yrs., graft vs.host dis.treatm, substit.
   adult use theref.data on use in pregn.& lactat.not avail.  for equine anti-lymphocyte immunoglobulin when intol. evid./ lat-  TWINRIX, GSK [P/S]
   Side effects: Loc.reacts.from redn.to haematoma at inj site, irritabil.,   ter contra-indicat.  Hepatit.A virus antigen 720 ELISA units, r-DNA Hepatitis B virus
   drowsin., convuls.incl febr. convuls, diarrh., naus., vomit., skin rash,   (S4) IV INFUS. W/30.2/75. 25 mg/5 ml  surf.antigen 20 µg/1 ml.
   uticar., prurit., appetite lost, abnorm.cry., allerg.reacts. incl.allerg./  892499-003: 1 vial, R2 766,69  Indications: Active immunisat.against hepatit.A & B in adults &
   atopic dermatit./eczema., apnoea, angioed., anaphylax., Kawasaki   Dosage: Posology depend.on indicat./admin. regim & other immuno-  childr.&gt; 1 yr. Expect.hepatit.D prophylax. as it does not occur in the
   dis., headache, fev., hypoton.-hyporespons.epis.  suppress.agent combinat. Admin. dly reqd.corticoster.& antihistam.  absenc.of hepatit.B infect.
   Warnings and special precautions: Review med. hist.esp.prev.   dos.prior to infus. Infus.aft.dil.in isoton.0,9% NaCl or 5% dextr.sol.   (S4) INJ, 32/30.1/0244
   vacccinat., suit.facilit.to respond to poss.anaphylax., postpone vac-  into large vein. Tot.infus.durat.of at least 4 hrs.  706829-001: 1x20 µg prefill.syr., R325,55
   cin.in ac. sev.febrile illn., thrombocytopen./any coagulat. disords.,   Immunosuppress.in transplantat: Ac.graft reject.prophylax:   Dosage: Admin.IM in deltoid reg.for adults and old.childr./ante-
   safety & immunogenicity data in childr.at incr.risk of pneumono-  1-1,5 mg/kg/day x2-9 days aft. kidn./pancreas./liv.transplantat & x2-5   rolat.thigh for infts.
   cocc.infects.not avail., reduc. antibody respons.with imp.immune   days aft. heart transplant. Correspond.cumulat.dos: 2-7,5 mg /kg in   Recomm.dos: Adults & childr.&gt; 1 yr: 1 ml
   responsivesn., poss. apnoea risk & 42-72 hr.resp.monit.for very   heart transplantat. & 2-13,5 mg/kg for other organs.  Adults & adolesc.16 yrs and old: Prim.vaccinat. sched.consists
   premat. infts.(&lt;28 wks.gestat.)& those with resp. immaturity hist.  Ac.graft reject: 1,5 mg/kg/day x3-14 days, correspond.to cumulat.  of 3 dos.1  at elect.date, 2  1 mnth later & 3  6 mnths.aft.1  dos.
                                                                         nd
                                                                                  rd
                                                                  st
                                                                                       st
   reqd.as benefits.of vaccinat.high & vaccinat.should not be withheld/  dos.of 4,5-21 mg/kg.  Childr.1-15 yrs: Prim.vaccinat.sched.consists of 2 dos.1  at elect.
                                                                                      st
   delay., no protect. against pneumococc.serogroups other than those   Sev.aplast.anaem: 2,5-3,5 mg/kg/day x 5 consec. days, correspond.  date, 2   6-12 mnths.aft.1  dos.
                                                                         st
                                                                 nd
   incl., antibody respons.to diphther./tetanus toxoid & prot.D does   to cumulat.dos.of 12,5-17,5 mg/kg.  Contra-indications: Ac.sev.febrile illn., hypersens. reacts.to prev.
   occur but does not substit.rout. diphth. /tetanus/ H influenzae type   Ac.&chron.graft vs.host dis.prophylax: Mismatch. relat./  monoval.hepatit.A/B vacc., intravasc.admin., post-expos.prophy-
   B vaccinat., protective immune respons.not elicit.in all vaccinees,   match.unrelat.donors: Adults: Prelimin.ther: 2,5 mg/kg/day from   lax., IV admin.
   prophylact.admin.of antipyret.may reduc. post-vaccinat.febrile re-  day-4 to day-2 or-1 correspond.to cumulat.dos.of 7,5-10 mg/kg.  Side-effects: Loc.reacts., fatigue, irritabilit., drowsin., headache,
   acts.however data suggest.prophylact.paracet.may reduc.immune   Graft vs.host dis.treatm: Indiv. Usually betw.2-5 mg/kg/day x5 days.  malaise, fev., GI disords., flu-like sympts., allerg. reacts.incl.anaphy-
   respons. to pneumococc.vacc.  Contraindications: Ac.infects.which C/I addit. immunosuppress.,   lax.& convuls., syncope, hypotens., centr.& periph. neurolog. disords.
                                safety in pregn.& lactat.not est.
   TETAGAM IM, NBI [P/S]                                      incl. Bells palsy/ Guillain-Barre syndr., thrombocytopen., bld.dycsras.,
                                                              skin reacts., vasculit.
   Human tetanus immunoglobulin deriv.from pooled human plasma   Special precautions: Admin.other vaccines at diff.inj.sites, do not
   with high titre of antibodies to tetanus toxin, test.& found non-react.  mix with other vaccines in same syringe, adeq.immunolog.respon.
   to HBsAg & antibodies to HCV, HIV-1 & HIV-2 viruses.       may.not achieved in immunosuppress.treatm./ immunodefic. pts.,
   Indications: Post-expos.tetanus prophylax.aft. tetanus-prone injur.in   The possibility of   pregn.& lactat., admin.SC in pts. with thrombocytopen./bleed.disor-
   pts. not adeq. vaccinat./pts. whose immunisat.stat.not known /pts.   drug accumulation   ds., childr.1-15 yrs.always admin.2  dos.to assure protect. against
                                                                             nd
   with sev. defic.in antibody product., ther.of clinic.manifest tetanus.  hepatit.B, booster poss.advis.in pts.at risk whose anti-HBs antibody
   (S4) IM INJ. T/30.2/743, 744.          should be           titre falls below 10 IU/l., addit.vaccinat.poss.necess.in haemodi-
   812919-009: 250 IU/ml, 1x2 ml amp, R232,54                 alys.& imp. immune syst., poss.incubat.period at time of vaccinat.
   804150-028: 500 IU/ml, 1x1 ml amp, R386,26  considered in   eff.not known, infect.caus.by other agents not prev., syncopy can
   Dosage: Admin.IMI.                                         occas.follow./ bef. any vaccinat.as psychogen.respon.to needle inj.
   Prophylax: 250 IU. Admin.500 IU if 24 hrs.has passed/if there is   the presence of
   risk of heavy contaminat.           significant renal or   TYPHIM Vi, Sanofi Aventis [P/S]
   Treatm: Clinic.tetanus: 3 000-6 000 IU as sngl. dos. May be used   Purif.Vi capsul.polysacchar.of Salmonella typhi (Ty 2 strain)
   to treat clinic.tetanus by wound site infiltrat. & IMI.  hepatic impairment.  25 µg/0,5 ml dos.
   Contraindications: Weigh risk-benef.-ratio of pts. with IgA defic.  Indications: Act.immunisat.against typhoid fev. caus. by Salmonella
   hist.or sev.anaphylact.reacts.to plasma products, IV inj.due to risk of   typhi.intend.for inhabit.of/ travell. to endem.zones, migrants, health
   shock, safety in pregn.& lactat.not est.                   care work., catering & food indust.prof, milit.person.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page376.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>&nbsp;&nbsp;&nbsp;<a href="page379.html">379</a>&nbsp;&nbsp;&nbsp;<a href="page380.html">380</a>&nbsp;&nbsp;&nbsp;<a href="page381.html">381</a>&nbsp;&nbsp;&nbsp;<a href="page382.html">382</a>
             </td>
             <td width="35%"><a href="page378.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page378.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
